Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy? (2013)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- Subjects: REGRESSÃO LOGÍSTICA; NEOPLASIAS COLORRETAIS (QUIMIOTERAPIA); PROGNÓSTICO
- Language: Inglês
- Imprenta:
- Source:
- Título: European Journal of Cancer
- ISSN: 0959-8049
- Volume/Número/Paginação/Ano: v. 49, supl 2, p. S288, res. 1369, 2013
- Conference titles: European Cancer Congress 2013 Abstract Book
-
ABNT
CROSARA, M. A. T. et al. Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529. Acesso em: 01 fev. 2026. , 2013 -
APA
Crosara, M. A. T., Marques, D. F., Ferrari, A. C., Alves, M. F. S., Alex, A. K., Sabbaga, J., et al. (2013). Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy? European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529 -
NLM
Crosara MAT, Marques DF, Ferrari AC, Alves MFS, Alex AK, Sabbaga J, Hoff PMG, Riechelmann R. Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy? [Internet]. European Journal of Cancer. 2013 ; 49 S288.[citado 2026 fev. 01 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529 -
Vancouver
Crosara MAT, Marques DF, Ferrari AC, Alves MFS, Alex AK, Sabbaga J, Hoff PMG, Riechelmann R. Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy? [Internet]. European Journal of Cancer. 2013 ; 49 S288.[citado 2026 fev. 01 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529 - Primary prevention of colorectal cancer: Myth or reality?
- Drogas moleculares
- Perspectivas no cuidado dos tumores gastrointestinais
- Obesidade e câncer
- Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
- Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
- Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
- Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy
- Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
- Quimioterapia sistemica neoadjuvante em câncer epitelial avançado de ovário/peritôneo/tuba uterina: estratégia para obtenção de citorredução ótima
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
